Douglas D. Taylor | Academic Influence

Douglas D. Taylor's AcademicInfluence.com Rankings

Douglas D. Taylor

Engineering

#8563

World Rank

#10132

Historical Rank

#1530

USA Rank

Electrical Engineering

#2677

World Rank

#2815

Historical Rank

#360

USA Rank

engineering Degrees

Douglas D. Taylor

Computer Science

#11587

World Rank

#12294

Historical Rank

#2035

USA Rank

Computational Linguistics

#2934

World Rank

#2967

Historical Rank

#87

USA Rank

Machine Learning

#5323

World Rank

#5390

Historical Rank

#212

USA Rank

Artificial Intelligence

#5742

World Rank

#5825

Historical Rank

#326

USA Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Douglas D. Taylor's Degrees

PhD Computer Science Stanford University

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2024

Why Is Douglas D. Taylor Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles. Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University. Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky. He was also on the faculty of the University of California, Davis. From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences.

(See a Problem?)

Douglas D. Taylor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. (2008) (2279)
Exosomal microRNA: a diagnostic marker for lung cancer. (2008) (1201)
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. (2005) (446)
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments (2011) (365)
Exosome isolation for proteomic analyses and RNA profiling. (2011) (359)
Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling1 (2006) (308)
Specific Isolation of Placenta‐Derived Exosomes from the Circulation of Pregnant Women and Their Immunoregulatory Consequences 1 (2006) (293)
T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. (2003) (250)
Identifying mRNA, MicroRNA and Protein Profiles of Melanoma Exosomes (2012) (243)
Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. (2012) (210)
Morphologic and proteomic characterization of exosomes released by cultured extravillous trophoblast cells. (2011) (151)
Trophoblast‐Derived Exosomes Mediate Monocyte Recruitment and Differentiation (2011) (147)
The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids (2013) (120)
Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy (2016) (120)
Human Trophoblast‐Derived Exosomal Fibronectin Induces Pro‐Inflammatory Il‐1β Production by Macrophages (2011) (119)
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. (2009) (94)
TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes. (2010) (83)
Potentiation of the radiation effect with genistein in cervical cancer cells. (2005) (73)
Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. (2004) (71)
Exosome platform for diagnosis and monitoring of traumatic brain injury (2014) (70)
Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity (1997) (67)
A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. (2003) (63)
Inhibition of Endometrial Cancer Cell Lines by Mifepristone (RU 486) (1998) (60)
HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. (2006) (56)
Cellular response to chemotherapy and radiation in cervical cancer. (2005) (55)
Characterization of plasma membrane shedding from murine melanoma cells (1988) (53)
Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. (2010) (46)
Shed membrane fragment-associated markers for endometrial and ovarian cancers. (2002) (44)
“Membrane‐Associated” Immunoglobulins in Cyst and Ascites Fluids of Ovarian Cancer Patients * (1983) (43)
Shed Membrane Fragment-Associated Markers for Endometrial and Ovarian Cancers (2002) (41)
Modulation of T-cell CD3-zeta chain expression during normal pregnancy. (2002) (41)
Human chorionic gonadotropin promotes tumorigenesis of choriocarcinoma JAr cells (1999) (40)
Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. (2006) (36)
Endometriosis Markers: Immunologic Alterations as Diagnostic Indicators for Endometriosis (2007) (35)
Shed membrane fragment modulation of CD3-zeta during pregnancy: link with induction of apoptosis. (2002) (34)
Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. (2006) (30)
Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels (2009) (27)
Identification of Antigenic Components Recognized by “Membrane‐Bound” Antibodies From Ovarian Cancer Patients (1984) (20)
Gene expression profiling in response to estradiol and genistein in ovarian cancer cells. (2009) (20)
Pregnancy-linked suppression of TcR signaling pathways by a circulating factor absent in recurrent spontaneous pregnancy loss (RPL). (2006) (19)
Loss of communication in ovarian cancer. (2006) (19)
Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] (2010) (17)
Alterations in Antibody Subclass Immune Reactivity to Trophoblast‐derived Fetal Fibronectin and α2‐Macroglobulin in Women with Recurrent Pregnancy Loss (2012) (16)
Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components. (2010) (14)
Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. (2006) (13)
Alterations in T-cell signal transduction molecules associated with recurrent spontaneous pregnancy loss. (2004) (13)
Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. (2003) (13)
Modulation of T‐Cell CD3‐Zeta Chain Expression in Early Pregnancy * (2002) (13)
SHED MEMBRANE VESICLES: A MECHANISM FOR TUMOR-INDUCED IMMUNOSUPPRESSION (1985) (12)
Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. (2004) (12)
Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient (2009) (10)
Neoplastic and Developmental Importance of Shed Plasma Membrane Fragments (1986) (9)
Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study. (2007) (9)
Effect of retinoic acid on tumor‐mediated immunologic alterations in mice bearing a variant of the ß16 melanoma (1990) (9)
Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. (1996) (8)
Differential expression of TcR-CD3 zeta as evidence for altered immunoregulation in preeclamptic versus normotensive women. (2003) (8)
Ovarian Cancer-Derived Exosomal Fibronectin Induces Pro-Inflammatory IL-1β (2013) (7)
ORIGINAL ARTICLE: Genistein Reverses Diminished T‐Cell Signal Transduction, Induced by Post‐Menopausal Estrogen Levels (2008) (5)
Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. (2005) (5)
Identification of Immunoreactive Tumour Antigens Using Free and Exosome-Associated Humoral Responses (2013) (3)
Genistein reverses diminished T cell signal transduction induced by postmenopausal estrogen levels (2008) (3)
Identification of a Unique Form of p53 in Human Cord Blood Associated with the Development of Maternal Autoantibodies (1998) (3)
cDNA Microarray Analysis of Gene Expression in Ovarian Cancer Cells After Treatment with Carboplatin and Paclitaxel (2006) (2)
Modulation of colon tumor oncogene expression by cancer patient‐derived lipids (1996) (2)
Abstract 5067: Identifying exosomal mRNA, microRNA and protein signatures in melanoma cells (2011) (2)
Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. (2012) (2)
Exosomal microRNA Signatures in the Diagnosis and Prognosis of Ovarian Cancer (2013) (1)
Failure of antigen-specific immune tolerance in recurrent spontaneous aborters (1998) (1)
Circulating Cell-derived Vesicles Mediate Tumor Progression (2013) (1)
Abstract 511: Characterization of humoral response profiles of ovarian cancer patients as diagnostic biomarkers (2012) (1)
Announcing Exosomes and Microvesicles, the Official Journal of the American Society for Exosomes and Microvesicles (2013) (1)
Normotensive Women (2006) (1)
Abstract B82: Exosomes derived from ascitic fluid of patients with ovarian carcinoma induce IL-4 gene expression in T lymphocytes (2015) (1)
Alterations in antibody immune responses and trophoblast antigens recognized in women with recurrent pregnancy loss (2010) (1)
Abstract 1947: Tumor-derived circulatory exosomal miRNAs as biomarkers of recurrent lung tumors. (2013) (0)
Model for Tumor-Host Interaction: Mechanism of Suppression Suppression of Wound Healing in Tumor Bearing Animals as a (2006) (0)
Exosomal microRNA signatures in the diagnosis and prognosis 5 a . CONTRACT NUMBER Of ovarian cancer (2014) (0)
P-415: Differential modulation Hsp60 and Hsp90α by HRT components in breast cancer cells (2006) (0)
Decreased IL-2 production from T cells in a low estrogen environment (2007) (0)
Award Number: W81XWH-10-1-0196 TITLE: Exosomal microRNA signatures in the diagnosis and prognosis of ovarian cancer (2014) (0)
MÃ © all detection of autoantibodies to diagnose and characterize disorders (2008) (0)
Sinking and decomposition of non-silicified planktonic algae of Douglas Lake. (1986) (0)
Identification of Galectin-9 on exosomes from human blastocyst culture medium (2013) (0)
Micro-associated RNA exosome as a diagnostic marker (2008) (0)
Biomarqueurs de cancer (2010) (0)
Evaluation of immune function in patients with hereditary cancers (2013) (0)
Zeta-Chain Regulation in Early Pregnancy (2000) (0)
Correlations between relative abundances of cyanophytes and chlorophytes and light attenuation in Douglas Lake, Cheboygan Co., Michigan. (1986) (0)
595 Decreased expression of CD3-zeta and induction of T-cell apoptosis by shed placental membrane fragments in maternal sera (2001) (0)
P-431: Progestogen inhibition of tissue inhibitor of metalloproteinase (TIMP)-2 in breast cancer cells (2006) (0)
Exosomal Long Non-Coding RNA (LNCRNA) in Lung Cancer (2012) (0)
000232 ROLE OF SUBOPTIMAL TREATMENT IN RESISTANCE TO CHEMOTHERAPY (2005) (0)
Aerosolized γ-Interferon and Lipopolysaccharide Enhances Cytotoxicity of Murine Pulmonary Alveolar Macrophages (1991) (0)
Variations in cytokine and estrogen receptor GPR30 expression in monocytes exposed to different estrogen environments (2010) (0)
Gene expression profiling of cardiovascular disease markers in response to hormone therapy in post-menopausal coronary artery vascular endothelium (2007) (0)
Induction of asymmetric IgG in ovarian cancer patients as a mechanism of tumor-specific immunosuppression (1998) (0)

This paper list is powered by the following services:

Other Resources About Douglas D. Taylor

en.wikipedia.org

What Schools Are Affiliated With Douglas D. Taylor?

Douglas D. Taylor is affiliated with the following schools: